ESPR
insider transactionsEsperion Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-115.6K
0 buy · 115.6K sell
Net value · 365d
-$347.6K
$0 in · $347.6K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
7
0 buy · 115.6K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Chief Legal Officer
$37.3K
11.8K sh · $3.16
Own -2%
-
Sell·S
President and CEO
$169.1K
53.6K sh · $3.16
Own -2%
-
Sell·S
Chief Financial Officer
$34.0K
10.8K sh · $3.16
Own -2%
-
Grant·A
Director
$0
79.9K sh
Own New
-
Grant·A
Director
$0
79.9K sh
Own +94%
-
Grant·A
Director
$0
79.9K sh
Own +1513%
-
Grant·A
Director
$0
79.9K sh
Own +131%
-
Grant·A
Director
$0
79.9K sh
Own +82%
-
Sell·S
Chief Legal Officer
$15.4K
5.7K sh · $2.70
Own -1%
-
Sell·S
President and CEO
$69.5K
25.6K sh · $2.72
Own -1%
-
Sell·S
Chief Financial Officer
$17.4K
6.4K sh · $2.71
Own -1%
-
Grant·A
Chief Legal Officer
$0
269.2K sh
Own New
-
Grant·A
Chief Legal Officer
$0
300.8K sh
Own +78%
-
Grant·A
President and CEO
$0
647.5K sh
Own New
-
Grant·A
President and CEO
$0
723.8K sh
Own +49%
-
Grant·A
Chief Financial Officer
$0
221.3K sh
Own New
-
Grant·A
Chief Financial Officer
$0
247.4K sh
Own +52%
-
Sell·S
General Counsel
$4.9K
1.7K sh · $2.88
Own -0%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Benjamin Looker | Sell S | 11.8K | $37.3K |
| Jun 17, 2026 | Sheldon L. Koenig KEY | Sell S | 53.6K | $169.1K |
| Jun 17, 2026 | Benjamin Halladay KEY | Sell S | 10.8K | $34.0K |
| May 28, 2026 | John Craig Thompson | Grant A | 79.9K | $0 |
| May 28, 2026 | Jay Shepard | Grant A | 79.9K | $0 |
| May 28, 2026 | Robert E. Hoffman | Grant A | 79.9K | $0 |
| May 28, 2026 | Seth H. Z. Fischer | Grant A | 79.9K | $0 |
| May 28, 2026 | Martin J Carroll | Grant A | 79.9K | $0 |
| Mar 17, 2026 | Benjamin Looker | Sell S | 5.7K | $15.4K |
| Mar 17, 2026 | Sheldon L. Koenig KEY | Sell S | 25.6K | $69.5K |
| Mar 17, 2026 | Benjamin Halladay KEY | Sell S | 6.4K | $17.4K |
| Mar 13, 2026 | Benjamin Looker | Grant A | 269.2K | $0 |
| Mar 13, 2026 | Benjamin Looker | Grant A | 300.8K | $0 |
| Mar 13, 2026 | Sheldon L. Koenig KEY | Grant A | 647.5K | $0 |
| Mar 13, 2026 | Sheldon L. Koenig KEY | Grant A | 723.8K | $0 |
| Mar 13, 2026 | Benjamin Halladay KEY | Grant A | 221.3K | $0 |
| Mar 13, 2026 | Benjamin Halladay KEY | Grant A | 247.4K | $0 |
| Jan 20, 2026 | Benjamin Looker | Sell S | 1.7K | $4.9K |
About ESPR insider trading
This page tracks insider transactions for Esperion Therapeutics, Inc. (ESPR) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.